SpaceOAR Vue Hydrogel Global Clinical Trial Update – 1st Patient Enrolled at Genesis Care

For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal (GI) toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy (SBRT) for the treatment of prostate cancer.

SpaceOAR Vue Hydrogel global clinical trial – Genesis Care—one of the leading oncology providers in the United States, Australia, Spain and the United Kingdom—today announced enrollment of the first patients.

SBRT uses a higher dose of radiation per treatment than traditional radiation therapy, which means fewer sessions are required, alleviating the time-intensive burden of treatment and allowing patients to return to their normal schedules sooner. This high-dose radiation is a highly effective form of cancer treatment, however, it can damage surrounding organs, which may lead to side effects for patients.

The SABRE trial, sponsored by Boston Scientific Corporation, will evaluate the effectiveness of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life for patients.

GenesisCare radiation oncologists Dr. Thomas Boike in Troy, Michigan is participating in the trial, and among the first to offer patients access to the hydrogel as part of the trial.

Michigan-based patient Charles Shulte said: “I am grateful for the opportunity to participate in this trial as I was recently diagnosed with prostate cancer by my physician who referred me to GenesisCare for ongoing treatment. I am hopeful this will lessen the effects that I currently have. It’s comforting to know Dr. Boike is going above and beyond to provide me access to the latest treatment, while looking out for my health and safety along the way.”

Prostate cancer is the second leading cause of cancer death in American men. The American Cancer Society reports that one in every 41 men will die from untreated later-stage prostate cancer. One in eight will be diagnosed with the disease during his lifetime.

“Since we use the most advanced and innovative radiotherapy as a standard, we look for ways to extend the effectiveness of SBRT, so a minimal amount of healthy tissue is exposed during treatment,” said Dr. Thomas Boike, MD. “With most patients eager to take action immediately after diagnosis, advances like SpaceOAR Vue Hydrogel from Boston Scientific plays a significant and important role in patients’ quality of life and prostate cancer treatment journey.”

SpaceOAR Vue Hydrogel works hand-in-hand with SBRT prostate cancer treatments by creating a temporary space between the prostate and the rectum, which is designed to reduce the radiation dose to the rectum, minimizing the impact on patients’ urinary, sexual and bowel functions.

GenesisCare Chief Global Medical Officer, Dr. Wally Curran, adds: “GenesisCare’s participation in this clinical trial is one example of how we seek to increase access to innovative research that addresses each individual patient’s needs. Advanced approaches to cancer treatment can positively impact a patient’s treatment plan and, most importantly, their recovery. The opportunity to work with Boston Scientific on this trial creates a chance to design better care options and experiences now and in the future.”

GenesisCare is an Australian headquartered private company and is one of the world’s largest cancer treatment providers. The organization has committed more than $300 million to upgrade technology and cancer treatment services across the United States. Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. This includes our 293 locations in the U.S., 40 locations in Australia, 14 in the U.K., and 16 in Spain. Globally, the organization employs more than 6000 highly trained physicians, healthcare professionals and support staff across Australia, the UK, Spain, and now in the U.S.

GenesisCare is heavily focused on clinical research and innovation in healthcare and leads or is a part of more than 150 clinical trials worldwide.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy